Navigation Links
AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
Date:10/5/2009

    UPPSALA, Sweden, October 5 /PRNewswire-FirstCall/ --
    - A New Miniaturized PCR Instrument With SuperConvection(TM)
    - At One Sixth the Price of QuanTyper(TM) Without Loss of Performance
    - Next Generation of PCR Expected to Rapidly Penetrate the Market

AlphaHelix (Ticker: ALPH) has in a very short time developed a miniaturized PCR-instrument - AmpXpress(TM) - to meet demands for lower instrument prices. This was made possible through know-how obtained during the development of QuanTyper(TM). AmpXpress(TM) is substantially smaller in size and weight, silent, consumes less power and will attract customers that are looking for a fast, simple and easy to use PCR-instrument with SuperConvection(TM). AlphaHelix expects a rapid penetration of the market as the price of AmpXpress(TM) is comparable to low-end thermal cyclers (without a rotary format). The sales price of AmpXpress(TM) is only one sixth of the price of QuanTyper(TM) (the first version of AmpXpress(TM) is however a standard PCR instrument, and does not feature real-time detection (qPCR). AmpXpress(TM) will be presented tomorrow at the BIOTECHNICA show in Hannover, Germany.

More information about AmpXpress(TM) is found at http://www.alphahelix.com. The product development has cost approximately 500 KSEK (gross). AlphaHelix has also been granted 250 KSEK by the Swedish Agency for Economic and Regional Growth. A first series of ten instruments has been initiated and patent applications have been submitted.

Technology assessment of SuperConvection and QuanTyper(TM) proceeds at the American biotechnology company and is not affected by the launch of AmpXpress(TM). Results from the evaluation are expected early November, at the earliest.

AlphaHelix Molecular Diagnostics AB (publ) develops instruments for rapid DNA analysis. The company's patented technology enables identification of virus and bacteria faster and with greater sensitivity than other technology available on the market. The AlphaHelix share is traded at AktieTorget http://www.aktietorget.se, which is a multilateral trading facility for small caps under the supervision of the Swedish Financial Supervisory Authority.

SOURCE AlphaHelix Molecular Diagnostics AB


'/>"/>
SOURCE AlphaHelix Molecular Diagnostics AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
2. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
3. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
4. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
5. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
6. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
7. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
8. iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference
9. Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Village, CA (PRWEB) , ... August 17, 2017 ... ... technology for cancer research and personalized medicine, today announced the launch of a ... Kansas City, Missouri. The study’s goal is to evaluate the potential for early ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics Inc ... $2M in funding from an impressive group of investors, including Rev1 Ventures, Maumee ... With this investment, 3Bar is broadening availability of its groundbreaking offering that uses ...
(Date:8/15/2017)... Charlotte, NC (PRWEB) , ... August 15, 2017 , ... ... in 2017, celebrating 10 years of successes helping medical technology companies and inventors develop ... company to a renowned full-service national engineering firm with a portfolio of clients in ...
(Date:8/15/2017)... , ... August 15, 2017 , ... The Conference ... on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The ... 7-9, 2018, at The Roosevelt Hotel in New York City. , “With our experience ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):